<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Biomedicines</journal-id>
<journal-id journal-id-type="iso-abbrev">Biomedicines</journal-id>
<journal-id journal-id-type="publisher-id">biomedicines</journal-id>
<journal-title-group>
<journal-title>Biomedicines</journal-title>
</journal-title-group>
<issn pub-type="epub">2227-9059</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32183098</article-id>
<article-id pub-id-type="pmc">7148495</article-id>
<article-id pub-id-type="doi">10.3390/biomedicines8030058</article-id>
<article-id pub-id-type="publisher-id">biomedicines-08-00058</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Unraveling the Role of Inwardly Rectifying Potassium Channels in the Hippocampus of an Aβ<sub>(1–42)</sub>-Infused Rat Model of Alzheimer’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3942-2097</contrib-id>
<name>
<surname>Akyuz</surname>
<given-names>Enes</given-names>
</name>
<xref ref-type="aff" rid="af1-biomedicines-08-00058">1</xref>
<xref ref-type="corresp" rid="c1-biomedicines-08-00058">*</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2730-5974</contrib-id>
<name>
<surname>Villa</surname>
<given-names>Chiara</given-names>
</name>
<xref ref-type="aff" rid="af2-biomedicines-08-00058">2</xref>
<xref ref-type="corresp" rid="c1-biomedicines-08-00058">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Beker</surname>
<given-names>Merve</given-names>
</name>
<xref ref-type="aff" rid="af3-biomedicines-08-00058">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Elibol</surname>
<given-names>Birsen</given-names>
</name>
<xref ref-type="aff" rid="af3-biomedicines-08-00058">3</xref>
</contrib>
</contrib-group>
<aff id="af1-biomedicines-08-00058"><label>1</label>Department of Biophysics, Faculty of Medicine, Yozgat Bozok University, Yozgat 66100, Turkey</aff>
<aff id="af2-biomedicines-08-00058"><label>2</label>School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy</aff>
<aff id="af3-biomedicines-08-00058"><label>3</label>Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul 34093, Turkey; <email>mbeker@bezmialem.edu.tr</email> (M.B.); <email>bcan@bezmialem.edu.tr</email> (B.E.)</aff>
<author-notes>
<corresp id="c1-biomedicines-08-00058"><label>*</label>Correspondence: <email>enesakyuz25@gmail.com</email> (E.A.); <email>chiara.villa@unimib.it</email> (C.V.)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>3</month>
<year>2020</year>
</pub-date>
<volume>8</volume>
<issue>3</issue>
<elocation-id>58</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>2</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>3</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a complex etiology and characterized by cognitive deficits and memory loss. The pathogenesis of AD is not yet completely elucidated, and no curative treatment is currently available. Inwardly rectifying potassium (Kir) channels are important for playing a key role in maintaining the resting membrane potential and controlling cell excitability, being largely expressed in both excitable and non-excitable tissues, including neurons. Accordingly, the aim of the study is to investigate the role of neuronal Kir channels in AD pathophysiology. The mRNA and protein levels of neuronal Kir2.1, Kir3.1, and Kir6.2 were evaluated by real-time PCR and Western blot analysis from the hippocampus of an amyloid-β(Aβ)<sub>(1-42)</sub>-infused rat model of AD. Extracellular deposition of Aβ was confirmed by both histological Congo red staining and immunofluorescence analysis. Significant decreased mRNA and protein levels of Kir2.1 and Kir6.2 channels were observed in the rat model of AD, whereas no differences were found in Kir3.1 channel levels as compared with controls. Our results provide in vivo evidence that Aβ can modulate the expression of these channels, which may represent novel potential therapeutic targets in the treatment of AD.</p>
</abstract>
<kwd-group>
<kwd>Alzheimer’s disease</kwd>
<kwd>amyloid beta</kwd>
<kwd>hippocampus</kwd>
<kwd>Kir channels</kwd>
<kwd>K<sup>+</sup> channels</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-biomedicines-08-00058" sec-type="intro">
<title>1. Introduction</title>
<p>Alzheimer’s disease (AD; MIM#104300) is a chronic irreversible neurodegenerative disorder and represents the most common form of dementia in elderly individuals [<xref ref-type="bibr" rid="B1-biomedicines-08-00058">1</xref>]. AD is clinically characterized by a progressive memory deterioration, thinking difficulty, confusion, and changes in personality, behavior, and language, resulting in autonomy loss that finally requires full-time medical care [<xref ref-type="bibr" rid="B2-biomedicines-08-00058">2</xref>]. The neuropathological hallmarks of AD include the presence of extracellular senile plaques constituted by the amyloid-β (Aβ) peptide and intracellular neurofibrillary tangles (NFTs) composed of hyper-phosphorylated paired helical filaments of the microtubule-associated protein tau (MAPT) [<xref ref-type="bibr" rid="B3-biomedicines-08-00058">3</xref>]. Among Aβ species, Aβ<sub>(1–42)</sub>, which is generated from Aβ precursor protein (APP) sequentially cleaved by β-secretase and γ-secretase, is considered more toxic than Aβ<sub>(1–40)</sub> because of its strong tendency to aggregate [<xref ref-type="bibr" rid="B4-biomedicines-08-00058">4</xref>]. The Aβ deposition in the brain triggers a series of neurodegenerative processes, including synaptic toxicity, microglia-mediated inflammation, mitochondrial dysfunction, and oxidative stress, which in turn lead to cell death [<xref ref-type="bibr" rid="B5-biomedicines-08-00058">5</xref>]. Furthermore, Aβ pathogenesis reduces the synthesis of acetylcholine (ACh) and negatively affects the acetylcholinesterase (AChE) activity [<xref ref-type="bibr" rid="B6-biomedicines-08-00058">6</xref>]. Despite its prevalence, the AD pathogenesis is not completely understood, and, currently, there are no effective treatments to slow or halt the progression of its symptoms [<xref ref-type="bibr" rid="B7-biomedicines-08-00058">7</xref>].</p>
<p>Emerging evidence points out a key role of ion channels in the progress and development of a variety of neurological disorders, including epilepsy [<xref ref-type="bibr" rid="B8-biomedicines-08-00058">8</xref>,<xref ref-type="bibr" rid="B9-biomedicines-08-00058">9</xref>], autism spectrum disorders [<xref ref-type="bibr" rid="B10-biomedicines-08-00058">10</xref>], multiple sclerosis [<xref ref-type="bibr" rid="B11-biomedicines-08-00058">11</xref>], and AD [<xref ref-type="bibr" rid="B12-biomedicines-08-00058">12</xref>]. Among them, the inwardly rectifying potassium (K<sup>+</sup>) channels (Kir) are essential for maintaining the resting membrane potential and controlling the cell excitability by the regulation intracellular and extracellular flow of K<sup>+</sup> ions in different types of cells, including neurons. To date, seven subfamilies (Kir1-Kir7) have been identified according to their sequence similarity and function properties [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>]. An important involvement of Kir2.x, Kir3.x, and Kir6.x channels in the pathogenesis of AD has been supported by both in vitro and in vivo models [<xref ref-type="bibr" rid="B11-biomedicines-08-00058">11</xref>]. Evidence showed an impaired activity or an altered expression of these channels, probably modulated by Aβ [<xref ref-type="bibr" rid="B12-biomedicines-08-00058">12</xref>,<xref ref-type="bibr" rid="B14-biomedicines-08-00058">14</xref>]. Given the limitations of investigating AD in human subjects, current studies mostly rely on animal models in order to understand the underlying molecular mechanisms of this disorder. Some experimental in vivo models mimicking the major neuropathological hallmarks in AD have already been developed for studying Kir channels in the disease pathogenesis [<xref ref-type="bibr" rid="B12-biomedicines-08-00058">12</xref>,<xref ref-type="bibr" rid="B15-biomedicines-08-00058">15</xref>], but no data are available regarding an Aβ<sub>(1–42)</sub>-infused rat model of AD.</p>
<p>Herein, we aim to better elucidate the role of Kir2.1, Kir3.1, and Kir6.2 channels in AD pathophysiology by analyzing their mRNA and protein levels in the hippocampus of an Aβ<sub>(1–42)</sub>-infused rat model of AD. This represents a valuable tool that recapitulates some key features of human AD, including Aβ plaque, cholinergic dysfunction, neuron loss, ventricular enlargement, and behavior deficiencies.</p>
</sec>
<sec id="sec2-biomedicines-08-00058">
<title>2. Materials and Methods</title>
<sec id="sec2dot1-biomedicines-08-00058">
<title>2.1. Animals</title>
<p>Adult female Sprague–Dawley rats (6-month-old; <italic>n</italic> = 14) were housed in a quiet, temperature and humidity-controlled room (21 ± 2 °C; 62% ± 7% relative humidity; 12-h cycles dark/light). Rats were fed ad libitum with a standard dry rat diet and tap water. All procedures were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals adopted by the National Institutes of Health (NIH, Bethesda, MD, USA) and the Declaration of Helsinki. Experimental protocol of this study was approved by the local scientific ethical committee of Bezmialem Vakif University, Istanbul, Turkey (2015/229). All efforts were made to minimize animal suffering.</p>
</sec>
<sec id="sec2dot2-biomedicines-08-00058">
<title>2.2. Aβ<sub>(1–42)</sub>-Infused Rat Model</title>
<p>A solvent of 35% acetonitrile plus 0.1% trifluoroacetic acid was used to reconstitute the Aβ<sub>(1–42)</sub> peptide (SCP0038, Sigma-Aldrich, St. Louis, MO, USA) and soluble peptide suspensions were incubated at 37 °C for 72 h with gentle shaking for fibril formation. The rats were injected intra-cerebroventricularly (ICV) with oligomeric Aβ<sub>(1–42)</sub> to induce AD. Briefly, after seven days of acclimation, rats were anesthetized with an intraperitoneal injection of a ketamine and xylazine mixture (100 and 10 mg/kg body weight, respectively) and then placed in a stereotaxic apparatus. A stainless steel cannula was stereotaxically implanted into the right hippocampus of rats (coordinates from bregma: −3.60 mm anteroposterior; −2.00 mm lateral; −4.00 mm vertical) and fixed to the skull with dental cement. A mini-osmotic pump (Alzet 2002, Durect, Cupertino, CA, USA) was attached and implanted subcutaneously near the scapula for a continual infusion.</p>
</sec>
<sec id="sec2dot3-biomedicines-08-00058">
<title>2.3. Experimental Design</title>
<p>Rats that underwent ICV infusion were randomly divided into two groups (<italic>n</italic> = 7 per group): (i) sham control that received injections of 0.9% NaCl saline solution, and (ii) Aβ<sub>(1–42)</sub>-infused group injected with Aβ<sub>(1–42)</sub> oligomers at the rate of 300 pmol/day for 14 days. Rats were sacrificed with decapitation after a 14-day infusion. The brains were quickly removed, and their both right and left hippocampi were dissected and then stored at −80 °C until molecular analysis.</p>
</sec>
<sec id="sec2dot4-biomedicines-08-00058">
<title>2.4. Histological Congo Red Staining</title>
<p>Coronal sections from the hippocampus were prepared at 20 μm thickness using a cryostat and fixed in ice-chilled 4% paraformaldehyde (PFA). For labeling Aβ deposits, slices were stained with 1% Congo red solution (Sigma-Aldrich, St. Louis, MO, USA) in 80% of absolute ethanol and 1% of NaOH. After being washed, sections were counterstained with cresyl violet, dehydrated in absolute ethanol, and then cleared in xylene. Specimens were mounted on slides and evaluated under a light microscope (Nikon Microscopy, Tokyo, Japan). For quantification, images were analyzed by color segmentation plugin–ImageJ software (NIH, Bethesda, MD, USA). The entire area of deposits was considered.</p>
</sec>
<sec id="sec2dot5-biomedicines-08-00058">
<title>2.5. Immunofluorescence Analysis</title>
<p>The PFA-fixed slices were blocked with 10% normal goat serum for 1 h. Sections were immunostained with the application of 1:100 dilution of primary anti-Aβ rabbit polyclonal antibody (8243, Cell Signaling Technology, Danvers, MA, USA) followed by goat anti-rabbit Alexa Fluor<sup>®</sup> 488 conjugated secondary antibody (A11034, Thermo Fisher Scientific, Waltham, MA, USA) at 1:200 dilution. Nuclei were marked blue with 40,6-diamidino-2-phenylindole (DAPI). The sections were mounted on slides and evaluated under a fluorescence microscope (Axio, Zeiss, Germany).</p>
</sec>
<sec id="sec2dot6-biomedicines-08-00058">
<title>2.6. cDNA Synthesis and Real-Time PCR</title>
<p>Total RNA was isolated from homogenized hippocampal tissue with TRIzol and PureLink RNA mini kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. One microgram of the total extract amount of RNA was treated with DNase I and reverse-transcribed using High Capacity cDNA Reverse Transcription Kit according to the manufacturer’s suggested protocol (Applied Biosystems, Foster City, CA, USA). The first-strand cDNA was used as a template for real-time PCR (RT–PCR) using rat specific primers for <italic>Kcnj2</italic> (Kir2.1), <italic>Kcnj3</italic> (Kir3.1), and <italic>Kcnj11</italic> (Kir6.2), as reported in <xref ref-type="table" rid="biomedicines-08-00058-t001">Table 1</xref>. RT–PCR reaction was performed with the SYBR Green PCR kit (iTaq™ Universal SYBR<sup>®</sup> Green, Biorad, Hercules, CA, USA) using a CFX96 real-time system sequence detector (Biorad, Hercules, CA, USA). Data, normalized to the housekeeping control gene (<italic>Gapdh</italic>), are expressed as fold change values respect to the sham control group according to the 2<sup>-ΔΔCt</sup> algorithm, as previously described [<xref ref-type="bibr" rid="B16-biomedicines-08-00058">16</xref>].</p>
</sec>
<sec id="sec2dot7-biomedicines-08-00058">
<title>2.7. Western blotting (WB)</title>
<p>Total protein extracts were obtained by lysing 0.25 g hippocampal tissue with 1 X RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1 % SDS) added with 1 mM DTT, 1 mM EDTA and EGTA, and 1.5% protease inhibitor cocktail and phosphatase inhibitor cocktail. Total protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) by a Multiskan™ GO Microplate spectrophotometer. Equal amounts of proteins were boiled for 5 min and separated by SDS–PAGE followed by transfer to PVDF membrane. Then, the membranes were blocked with 5% milk solution prepared in TBST (Tris-buffered saline, 0.1% Tween 20) buffer and incubated with one of the following primary antibodies against Kir2.1 (rabbit polyclonal, 1:200, Abcam, Cambridge, UK [ab65796]), Kir3.1 (mouse monoclonal, 1:200, Alomone Labs, Jerusalem, Israel [APC-005]), Kir6.2 (rabbit polyclonal, 1:200, Alomone Labs, Jerusalem, Israel [APC-020]), or β-actin (mouse monoclonal, 1:5000, Thermo Fisher Scientific, Waltham, MA, USA [AC-15]). Membranes were washed three times in TBST and then incubated with ECL anti-mouse or anti-rabbit horseradish peroxidase-conjugated IgG secondary antibodies (1:5000, GE Healthcare Life Sciences, Amersham, UK). The protein bands were developed with luminol-based substrate (Advansta, San Jose, CA, USA) and chemiluminescent signal was digitally acquired by CCD camera with Fusion FX7 (Vilber Lourmat, France) system. Densitometric analysis of Western blot bands was performed using the “gel analyzer” function of ImageJ software (NIH, Bethesda, MD, USA).</p>
</sec>
<sec id="sec2dot8-biomedicines-08-00058">
<title>2.8. Statistical Analysis</title>
<p>Data are generally given as mean values ± standard error of the mean (SEM). Pairwise comparisons were performed by Mann–Whitney U-test. The version 18 of Statistical Package for Social Science (SPSS 18, IBM Corporation, Chicago, IL, USA) was used for statistical analysis of the data. Differences were considered significant at * <italic>p</italic> &lt; 0.05 and ** <italic>p</italic> &lt; 0.01.</p>
</sec>
</sec>
<sec id="sec3-biomedicines-08-00058" sec-type="results">
<title>3. Results</title>
<sec id="sec3dot1-biomedicines-08-00058">
<title>3.1. Injection of Aβ<sub>(1–42)</sub> Oligomers Mimicked Alzheimer’s Disease in Rats</title>
<p>As a result of Aβ<sub>(1–42)</sub> infusion for 14 days, both Congo red histological staining and immunofluorescence analysis confirmed the extracellular presence of oligomeric and aggregated forms of Aβ in the hippocampus of rat model as compared with the sham control (2.73-fold change over sham controls, * <italic>p</italic> &lt; 0.05, <xref ref-type="fig" rid="biomedicines-08-00058-f001">Figure 1</xref>; 2.21-fold change over sham control, * <italic>p</italic> &lt; 0.05, <xref ref-type="fig" rid="biomedicines-08-00058-f002">Figure 2</xref>, respectively).</p>
</sec>
<sec id="sec3dot2-biomedicines-08-00058">
<title>3.2. Aβ<sub>(1–42)</sub>-Infused Rats Exhibited Low mRNA Levels of Neuronal Kir2.1 and Kir6.2 Channels</title>
<p>With the purpose of investigating a possible role of neuronal Kir channels in AD pathogenesis, we firstly analyzed mRNA levels of Kir2.1, Kir3.1, and Kir6.2 channels in both ipsilateral and contralateral hippocampi from rats by RT–PCR.</p>
<p>Significantly decreased mRNA levels of Kir2.1 (<italic>Kcnj2</italic>) and Kir6.2 (<italic>Kcnj11</italic>) channels were observed in both ipsilateral and contralateral hemispheres of Aβ<sub>(1–42)</sub>-infused rats as compared with sham controls (<xref ref-type="fig" rid="biomedicines-08-00058-f003">Figure 3</xref>A: 4.85-fold change and 3.15-fold change over controls, ** <italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="biomedicines-08-00058-f003">Figure 3</xref>C: 5.30-fold change and 3.00-fold change over controls, ** <italic>p</italic> &lt; 0.01 and * <italic>p</italic> &lt; 0.05, respectively). However, no significant differences were found in mRNA levels of the Kir3.1 (<italic>Kcnj3</italic>) channel in both hemispheres (<xref ref-type="fig" rid="biomedicines-08-00058-f003">Figure 3</xref>B, <italic>p</italic> &gt; 0.05).</p>
</sec>
<sec id="sec3dot3-biomedicines-08-00058">
<title>3.3. Low mRNA Levels of Kir2.1 and Kir6.2 Channels Correlate with Decreased Protein Levels in Aβ<sub>(1–42)</sub>-Infused Rat Model</title>
<p>In order to assess if changes in mRNA levels of Kir channels result in different protein levels, total protein extract from both ipsilateral and contralateral hippocampus tissues were analyzed via WB analysis by using specific anti-Kir antibodies and the relative protein abundance was quantified by densitometric measurements.</p>
<p>Significantly decreased Kir2.1 protein levels were detected only in the ipsilateral hemisphere of Aβ<sub>(1–42)</sub>-infused rats as compared with sham controls (<xref ref-type="fig" rid="biomedicines-08-00058-f004">Figure 4</xref>A: 0.41 ± 0.50 vs. 0.72 ± 0.25, ** <italic>p</italic> &lt; 0.01). Decreased Kir6.2 protein levels were observed in both ipsilateral and contralateral hippocampus tissues of Aβ<sub>(1–42)</sub>-infused rats as compared with sham controls (<xref ref-type="fig" rid="biomedicines-08-00058-f004">Figure 4</xref>C: 0.61 ± 0.35 vs. 0.82 ± 0.52, * <italic>p</italic> &lt; 0.05, and 0.52 ± 0.25 vs. 0.71 ± 0.40, * <italic>p</italic> &lt; 0.05, respectively). On the other hand, no significant differences in Kir3.1 protein levels were found in Kir3.1 protein levels in both hemispheres (<xref ref-type="fig" rid="biomedicines-08-00058-f004">Figure 4</xref>B, <italic>p</italic> &gt; 0.05), confirming previous mRNA data (<xref ref-type="fig" rid="biomedicines-08-00058-f003">Figure 3</xref>B).</p>
</sec>
</sec>
<sec id="sec4-biomedicines-08-00058" sec-type="discussion">
<title>4. Discussion</title>
<p>Functional and expression alterations of K<sup>+</sup> channels cause disruptions in neuronal balance and membrane excitability, contributing to the development and progress of several neurological diseases, including AD [<xref ref-type="bibr" rid="B8-biomedicines-08-00058">8</xref>,<xref ref-type="bibr" rid="B9-biomedicines-08-00058">9</xref>,<xref ref-type="bibr" rid="B10-biomedicines-08-00058">10</xref>,<xref ref-type="bibr" rid="B11-biomedicines-08-00058">11</xref>,<xref ref-type="bibr" rid="B12-biomedicines-08-00058">12</xref>]. Among them, Kir channels have the ability to mediate the inward flow of K<sup>+</sup> ions at hyperpolarizing membrane voltages more readily than the outward flow of K<sup>+</sup> at depolarizing voltages [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>]. They are involved in a number of essential physiological processes, such as the regulation of hormone secretion, generation of electrical impulses, and control of vascular smooth muscle tone. It is known that a variety of severe human disorders are directly related to a dysfunction of Kir channel proteins [<xref ref-type="bibr" rid="B17-biomedicines-08-00058">17</xref>]. Moreover, intracellular Na<sup>+</sup> and K<sup>+</sup> levels were found to be increased in brain regions of AD patients, pointing out a cellular ion imbalance in AD pathophysiology [<xref ref-type="bibr" rid="B18-biomedicines-08-00058">18</xref>]. So, given their function in maintaining the resting membrane potential and K<sup>+</sup> homeostasis of most cells [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>], we aim to highlight the role of neural Kir channels in AD by analyzing their mRNA and protein levels in the hippocampus of Aβ<sub>(1–42)</sub>-infused rat model of the disease.</p>
<p>The classical Kir2 subfamily exhibits a strong inward rectifying property and it is the major responsible for the <italic>I</italic><sub>K1</sub> current. Kir2.1 channels hyperpolarize the cells in response to an increase in the external K<sup>+</sup> concentration [<xref ref-type="bibr" rid="B19-biomedicines-08-00058">19</xref>]. Our data showed a decrease in both mRNA and protein levels of Kir2.1, suggesting a reduced Kir current in the hippocampus of AD model rats. We can speculate that Aβ peptide may decrease the expression of this channel, affecting the hippocampal activity balance underlying memory and learning processes damaged in AD [<xref ref-type="bibr" rid="B14-biomedicines-08-00058">14</xref>]. However, other authors reported no differences in Kir2.1 mRNA expression in the hippocampus of rats with cholinergic impairment, probably because of the use of different models [<xref ref-type="bibr" rid="B15-biomedicines-08-00058">15</xref>].</p>
<p>In addition to Kir2.1, a decrease in both transcript and protein levels of Kir6.2 channel has also been observed. In contrast with <italic>I</italic><sub>K1</sub> channels, Kir6 (also known as adenosine triphosphate (ATP)-sensitive K<sup>+</sup>, K<sub>ATP</sub>) subfamily are weakly inwardly rectifying and are inhibited by intracellular ATP levels [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>]. They correlate the metabolic status of neurons to their excitability by detecting changes of intracellular phosphate potential (e.g., ATP/ADP ratio) [<xref ref-type="bibr" rid="B20-biomedicines-08-00058">20</xref>]. Functional channels consist of four pore-forming Kir6 subunits (Kir6.1 and Kir6.2) and four sulfonylurea receptor (SUR) subunits (SUR1, SUR2 A, and SUR2 B). In neurons, the K<sub>ATP</sub> channels are mainly constituted by the coassembly of Kir6.2/SUR1 subunits [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>]. They are also involved in the generation of the glucose-sensitive K<sup>+</sup> current in neurons, indicating that the increase in neuronal excitation observed when the concentration of external glucose raises is due to the closure of K<sub>ATP</sub> channels [<xref ref-type="bibr" rid="B21-biomedicines-08-00058">21</xref>]. It is well-known that the Kir6 subfamily is involved in AD pathogenesis and phenotype [<xref ref-type="bibr" rid="B12-biomedicines-08-00058">12</xref>]. The first evidence has been addressed by a study in which increased transcript levels of Kir6.1 were observed in the hippocampus of cholinergic impaired rats, whereas mRNA expression of Kir6.2 was significantly increased in the cortex [<xref ref-type="bibr" rid="B15-biomedicines-08-00058">15</xref>]. Consistent with these findings, high Kir6.2 protein levels were also found in both hippocampal reactive astrocytes from a triple transgenic mouse model of AD (3 xTg-AD) [<xref ref-type="bibr" rid="B22-biomedicines-08-00058">22</xref>]. On the other hand, we found a decrease in both mRNA and protein levels of Kir6.2 in the hippocampus of Aβ<sub>(1–42)</sub>-infused rats. These contrasting results may be due to the use of different AD models. Interestingly, the transgenic overexpression of the Kir6.2 channel in the forebrain protects mice from neuronal damage and hypoxic–ischemic injury seen in stroke [<xref ref-type="bibr" rid="B23-biomedicines-08-00058">23</xref>]. Moreover, it has been shown that Kir6.2 knock-out mice showed severe deficits in long-term memory processes and learning [<xref ref-type="bibr" rid="B24-biomedicines-08-00058">24</xref>,<xref ref-type="bibr" rid="B25-biomedicines-08-00058">25</xref>]. Therefore, we can hypothesize that the impairment of memory occurring in AD may be related to a downregulation of the Kir6.2 subunit.</p>
<p>Concerning Kir3.1 channels, no statistical differences were found. Also named as G-protein-coupled Kir (GIRK) channels, they are activated by some neurotransmitters (e.g., acetylcholine GABA, dopamine) through the stimulation of their G protein coupled receptors (GPCRs), resulting in a reduced action potential firing and a cell membrane hyperpolarization. GIRK channels are detected in the extra-synaptic membrane of CA1 hippocampal pyramidal neurons and play a role in the production of slow inhibitory post-synaptic potential [<xref ref-type="bibr" rid="B13-biomedicines-08-00058">13</xref>]. However, our data did not show any significant differences in either transcript or protein levels of Kir3.1 channel in both hemispheres of hippocampus from the Aβ<sub>(1–42)</sub>-infused rat model, in line with an already reported study [<xref ref-type="bibr" rid="B15-biomedicines-08-00058">15</xref>]. We can speculate that this evidence may be due to two contrasting effects of Aβ on these channels in a more complex neuronal network. Indeed, it has been reported that this peptide led to a GIRK3 channel upregulation, which resulted in K<sup>+</sup> efflux from neurons triggering, thus, the Aβ-mediated apoptotic pathway [<xref ref-type="bibr" rid="B26-biomedicines-08-00058">26</xref>]. On the contrary, other authors reported an opposite effect of Aβ in which it modulated GIRK3 expression by downregulating these channels [<xref ref-type="bibr" rid="B14-biomedicines-08-00058">14</xref>].</p>
<p>In summary, our data support the evidence that Aβ can modulate the expression of neuronal Kir channels in the AD pathogenesis. The fact that we reported some results that are contrasting with the previous ones may be related to the use of different in vivo models that recapitulate distinct features of the disorder. Indeed, due to the lack of complete understanding of AD etiology, the development of adequate animal models resembling all stages of disease progression, as well as the merging convergent pathways of neurodegeneration, still represents a need for AD research. However, the complementary use of several models will help to understand molecular mechanisms underlying the disease and to develop novel strategies based on the modulation of Kir channels or their accessory subunits for AD prevention and therapy.</p>
</sec>
<sec id="sec5-biomedicines-08-00058" sec-type="conclusions">
<title>5. Conclusions</title>
<p>Overall, our data corroborate the working hypothesis that Kir channels play a causative role in AD pathogenesis, as suggested by their altered mRNA and protein levels found in the Aβ<sub>(1–42)</sub>-infused rat model. However, it cannot be excluded a complex mechanism of Aβ, which makes such reported alterations the result of an impaired metabolic pathway involving related channels or other proteins. We are aware that our study has several limitations, including the confirmation that differences observed in protein amounts are translated into an altered channel function activity by patch-clamp recordings and the lack of tests assessing learning and memory deficits. Moreover, it should be noted that, although cerebral infusion of Aβ in rats can recapitulate some hallmarks of human AD, it cannot properly reproduce the progressive neurodegeneration occurring during the disease, so further studies in different models are necessary to cover all aspects of the disease.</p>
</sec>
</body>
<back>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, E.A.; methodology, E.A. and B.E.; formal analysis, E.A., C.V., M.B. and B.E.; investigation, E.A., C.V., M.B. and B.E.; data curation, E.A., C.V., M.B. and B.E.; writing—original draft preparation, E.A., C.V., M.B. and B.E.; writing—review and editing, E.A., C.V., M.B. and B.E.; supervision, E.A., C.V. and B.E.; project administration, E.A. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This study was supported by the grant from Bezmialem Vakif University Scientific Research Found (BVU-BAP) (12.2014/2 and 9.2015/26).</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-biomedicines-08-00058">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crous-Bou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Minguillón</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gramunt</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Molinuevo</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease prevention: From risk factors to early intervention</article-title>
<source/>Alzheimers Res. Ther.
          <year>2017</year>
<volume>9</volume>
<fpage>71</fpage>
<pub-id pub-id-type="doi">10.1186/s13195-017-0297-z</pub-id>
<pub-id pub-id-type="pmid">28899416</pub-id>
</element-citation>
</ref>
<ref id="B2-biomedicines-08-00058">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Mahdi</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>Therapeutics of Alzheimer’s disease: Past, present and future</article-title>
<source/>Neuropharmacology
          <year>2014</year>
<volume>76 (Pt. A)</volume>
<fpage>27</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.07.004</pub-id>
<pub-id pub-id-type="pmid">23891641</pub-id>
</element-citation>
</ref>
<ref id="B3-biomedicines-08-00058">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanabria-Castro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alvarado-Echeverria</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Monge-Bonilla</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Molecular Pathogenesis of Alzheimer’s Disease: An Update</article-title>
<source/>Ann. Neurosci.
          <year>2017</year>
<volume>24</volume>
<fpage>46</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1159/000464422</pub-id>
<pub-id pub-id-type="pmid">28588356</pub-id>
</element-citation>
</ref>
<ref id="B4-biomedicines-08-00058">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haass</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Selkoe</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer’s amyloid beta-peptide</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <year>2007</year>
<volume>8</volume>
<fpage>101</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1038/nrm2101</pub-id>
<pub-id pub-id-type="pmid">17245412</pub-id>
</element-citation>
</ref>
<ref id="B5-biomedicines-08-00058">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tönnies</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trushina</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Oxidative stress, synaptic dysfunction, and alzheimer’s disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>57</volume>
<fpage>1105</fpage>
<lpage>1121</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-161088</pub-id>
<pub-id pub-id-type="pmid">28059794</pub-id>
</element-citation>
</ref>
<ref id="B6-biomedicines-08-00058">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martinez</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors</article-title>
<source/>Curr. Pharm. Des.
          <year>2006</year>
<volume>12</volume>
<fpage>4377</fpage>
<lpage>4387</lpage>
<pub-id pub-id-type="doi">10.2174/138161206778792985</pub-id>
<pub-id pub-id-type="pmid">17105433</pub-id>
</element-citation>
</ref>
<ref id="B7-biomedicines-08-00058">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangialasche</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Winblad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mecocci</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kivipelto</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s disease: Clinical trials and drug development</article-title>
<source/>Lancet Neurol.
          <year>2010</year>
<volume>9</volume>
<fpage>702</fpage>
<lpage>716</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(10)70119-8</pub-id>
<pub-id pub-id-type="pmid">20610346</pub-id>
</element-citation>
</ref>
<ref id="B8-biomedicines-08-00058">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akyuz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mega Tiber</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Beker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akbas</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Expression of cardiac inwardly rectifying potassium channels in pentylenetetrazole kindling model of epilepsy in rats</article-title>
<source/>Cell. Mol. Biol. (Noisy-le-grand)
          <year>2018</year>
<volume>64</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.14715/cmb/2017.64.15.8</pub-id>
</element-citation>
</ref>
<ref id="B9-biomedicines-08-00058">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Combi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Potassium Channels and Human Epileptic Phenotypes: An Updated Overview</article-title>
<source/>Front. Cell. Neurosci.
          <year>2016</year>
<volume>10</volume>
<fpage>81</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2016.00081</pub-id>
<pub-id pub-id-type="pmid">27064559</pub-id>
</element-citation>
</ref>
<ref id="B10-biomedicines-08-00058">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Binda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rivolta</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chisci</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cornaggia</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Giovannoni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Combi</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>A Novel KCNJ2 Mutation Identified in an Autistic Proband Affects the Single Channel Properties of Kir2.1</article-title>
<source/>Front. Cell. Neurosci.
          <year>2018</year>
<volume>12</volume>
<fpage>76</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2018.00076</pub-id>
<pub-id pub-id-type="pmid">29615871</pub-id>
</element-citation>
</ref>
<ref id="B11-biomedicines-08-00058">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akyuz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>A novel role of cardiac inwardly rectifying potassium channels explaining autonomic cardiovascular dysfunctions in a cuprizone-induced mouse model of multiple sclerosis</article-title>
<source/>Auton. Neurosci.
          <year>2020</year>
<volume>225</volume>
<fpage>102647</fpage>
<pub-id pub-id-type="doi">10.1016/j.autneu.2020.102647</pub-id>
<pub-id pub-id-type="pmid">32087534</pub-id>
</element-citation>
</ref>
<ref id="B12-biomedicines-08-00058">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Suphesiz</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Combi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Akyuz</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Potassium channels in the neuronal homeostasis and neurodegenerative pathways underlying Alzheimer’s Disease: An update</article-title>
<source/>Mech. Ageing Dev.
          <year>2019</year>
<volume>185</volume>
<fpage>111197</fpage>
<pub-id pub-id-type="doi">10.1016/j.mad.2019.111197</pub-id>
<pub-id pub-id-type="pmid">31862274</pub-id>
</element-citation>
</ref>
<ref id="B13-biomedicines-08-00058">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hibino</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inanobe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Furutani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Findlay</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kurachi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Inwardly rectifying potassium channels: Their structure, function, and physiological roles</article-title>
<source/>Physiol. Rev.
          <year>2010</year>
<volume>90</volume>
<fpage>291</fpage>
<lpage>366</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00021.2009</pub-id>
<pub-id pub-id-type="pmid">20086079</pub-id>
</element-citation>
</ref>
<ref id="B14-biomedicines-08-00058">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mayordomo-Cava</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yajeya</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Navarro-Lopez</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Jimenez-Diaz</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Amyloidbeta(25-35) modulates the expression of GirK and KCNQ channel genes in the Hippocampus</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0134385</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0134385</pub-id>
<pub-id pub-id-type="pmid">26218288</pub-id>
</element-citation>
</ref>
<ref id="B15-biomedicines-08-00058">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.H.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.L.</given-names>
</name>
</person-group>
<article-title>mRNA expression alterations of inward rectifier potassium channels in rat brain with cholinergic impairment</article-title>
<source/>Neurosci. Lett.
          <year>2002</year>
<volume>322</volume>
<fpage>25</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/S0304-3940(02)00071-X</pub-id>
<pub-id pub-id-type="pmid">11958835</pub-id>
</element-citation>
</ref>
<ref id="B16-biomedicines-08-00058">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serpente</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fenoglio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cortini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cantoni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ridolfi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Marcone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of OLR1 and its regulating hsa-miR369-3 p in Alzheimer’s disease: Genetics and expression analysis</article-title>
<source/>J. Alzheimers Dis.
          <year>2011</year>
<volume>26</volume>
<fpage>787</fpage>
<lpage>793</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2011-110074</pub-id>
<pub-id pub-id-type="pmid">21709374</pub-id>
</element-citation>
</ref>
<ref id="B17-biomedicines-08-00058">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zangerl-Plessl</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Qile</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bloothooft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stary-Weinzinger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>van der Heyden</surname>
<given-names>M.A.G.</given-names>
</name>
</person-group>
<article-title>Disease Associated Mutations in KIR Proteins Linked to Aberrant Inward Rectifier Channel Trafficking</article-title>
<source/>Biomolecules.
          <year>2019</year>
<volume>9</volume>
<elocation-id>650</elocation-id>
<pub-id pub-id-type="doi">10.3390/biom9110650</pub-id>
</element-citation>
</ref>
<ref id="B18-biomedicines-08-00058">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vitvitsky</surname>
<given-names>V.M.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Keep</surname>
<given-names>R.F.</given-names>
</name>
<name>
<surname>Albin</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Na+ and K+ ion imbalances in Alzheimer’s disease</article-title>
<source/>Biochim. Biophys. Acta.
          <year>2012</year>
<volume>1822</volume>
<fpage>1671</fpage>
<lpage>1681</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbadis.2012.07.004</pub-id>
<pub-id pub-id-type="pmid">22820549</pub-id>
</element-citation>
</ref>
<ref id="B19-biomedicines-08-00058">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anumonwo</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Lopatin</surname>
<given-names>A.N.</given-names>
</name>
</person-group>
<article-title>Cardiac strong inward rectifier potassium channels</article-title>
<source/>J. Mol. Cell. Cardiol.
          <year>2010</year>
<volume>48</volume>
<fpage>45</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2009.08.013</pub-id>
<pub-id pub-id-type="pmid">19703462</pub-id>
</element-citation>
</ref>
<ref id="B20-biomedicines-08-00058">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Adamo</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Catacuzzeno</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Di Giovanni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Franciolini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pessia</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>K(+) channelepsy: Progress in the neurobiology of potassium channels and epilepsy</article-title>
<source/>Front. Cell. Neurosci.
          <year>2013</year>
<volume>7</volume>
<fpage>134</fpage>
<pub-id pub-id-type="doi">10.3389/fncel.2013.00134</pub-id>
<pub-id pub-id-type="pmid">24062639</pub-id>
</element-citation>
</ref>
<ref id="B21-biomedicines-08-00058">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haider</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Antcliff</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Proks</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sansom</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Ashcroft</surname>
<given-names>F.M.</given-names>
</name>
</person-group>
<article-title>Focus on Kir6.2: A key component of the ATP-sensitive potassium channel</article-title>
<source/>J. Mol. Cell Cardiol.
          <year>2005</year>
<volume>38</volume>
<fpage>927</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2005.01.007</pub-id>
<pub-id pub-id-type="pmid">15910877</pub-id>
</element-citation>
</ref>
<ref id="B22-biomedicines-08-00058">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Griffith</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.X.</given-names>
</name>
<name>
<surname>Patrylo</surname>
<given-names>P.R.</given-names>
</name>
</person-group>
<article-title>Aberrant expression of the pore-forming KATP channel subunit Kir6.2 in hippocampal reactive astrocytes in the 3 xTg-AD mouse model and human Alzheimer’s disease</article-title>
<source/>Neuroscience
          <year>2016</year>
<volume>336</volume>
<fpage>81</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.08.034</pub-id>
<pub-id pub-id-type="pmid">27586053</pub-id>
</element-citation>
</ref>
<ref id="B23-biomedicines-08-00058">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Héron-Milhavet</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xue-Jun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Vannucci</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Willing</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Stannard</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hernandez-Sanchez</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mobbs</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Virsolvy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>LeRoith</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Protection against hypoxic-ischemic injury in transgenic mice overexpressing Kir6.2 channel pore in forebrain</article-title>
<source/>Mol. Cell Neurosci.
          <year>2004</year>
<volume>25</volume>
<fpage>585</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="doi">10.1016/j.mcn.2003.10.012</pub-id>
<pub-id pub-id-type="pmid">15080888</pub-id>
</element-citation>
</ref>
<ref id="B24-biomedicines-08-00058">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choeiri</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Staines</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Miki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Seino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Renaud</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Teutenberg</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Messier</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Cerebral glucose transporters expression and spatial learning in the K-ATP Kir6.2(-/-) knockout mice</article-title>
<source/>Behav. Brain. Res.
          <year>2006</year>
<volume>172</volume>
<fpage>233</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2006.05.005</pub-id>
<pub-id pub-id-type="pmid">16797737</pub-id>
</element-citation>
</ref>
<ref id="B25-biomedicines-08-00058">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Betourne</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bertholet</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Labroue</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Halley</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Lorsignol</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Z.P.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Penicaud</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lassalle</surname>
<given-names>J.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Involvement of hippocampal CA3 K(ATP) channels in contextual memory</article-title>
<source/>Neuropharmacology
          <year>2009</year>
<volume>56</volume>
<fpage>615</fpage>
<lpage>625</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.11.001</pub-id>
<pub-id pub-id-type="pmid">19059420</pub-id>
</element-citation>
</ref>
<ref id="B26-biomedicines-08-00058">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>May</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Anggono</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gooch</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Matusica</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kerbler</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Meunier</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Sah</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Coulson</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>G-protein-Coupled inwardly rectifying potassium (GIRK) channel activation by the p75 neurotrophin receptor is required for amyloid beta toxicity</article-title>
<source/>Front. Neurosci.
          <year>2017</year>
<volume>11</volume>
<fpage>455</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2017.00455</pub-id>
<pub-id pub-id-type="pmid">28848381</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="biomedicines-08-00058-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Representative images of hippocampus sections stained with Congo red in sham control and Aβ<sub>(1–42)</sub>-infused rat model. Extracellular Aβ deposits were visualized in brownish color and indicated by arrows; the nuclei were counterstained with cresyl violet (purple). Pictures were taken at the magnification of ×20. Scale bar: 20 µm.</p>
</caption>
<graphic xlink:href="biomedicines-08-00058-g001"></graphic>
</fig>
<fig id="biomedicines-08-00058-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Representative images of hippocampus section stained with anti-Aβ antibody (green fluorescence) in sham control and Aβ<sub>(1–42)</sub>-infused rat model. Cell nuclei were counterstained with DAPI (blue fluorescence). Scale bar: 50 µm.</p>
</caption>
<graphic xlink:href="biomedicines-08-00058-g002"></graphic>
</fig>
<fig id="biomedicines-08-00058-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Relative mRNA levels of (<bold>A</bold>) <italic>Kcnj2</italic> (Kir2.1), (<bold>B</bold>) <italic>Kcnj3</italic> (Kir3.1), and (<bold>C</bold>) <italic>Kcnj11</italic> (Kir6.2) in ipsilateral and contralateral hippocampi from both sham control and Aβ<sub>(1–42)</sub>-infused rat model. Data are expressed as fold change of mRNA levels normalized to the housekeeping control gene (<italic>Gapdh</italic>) and represent the mean ± SEM obtained in 3 independent experiments, <italic>n</italic> = 7 for each group, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01.</p>
</caption>
<graphic xlink:href="biomedicines-08-00058-g003"></graphic>
</fig>
<fig id="biomedicines-08-00058-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Protein expression levels of Kir2.1 (<bold>A</bold>), Kir3.1 (<bold>B</bold>), and Kir6.2 (<bold>C</bold>) channels in ipsilateral and contralateral hippocampi from both sham control and Aβ<sub>(1–42)</sub>-infused rat model. Upper panel: representative images of WB analysis on total protein extracts. β-actin was used as endogenous control for equal protein load. Lower panel: densitometric analysis of Kir2.1 (<bold>A</bold>), Kir3.1 (<bold>B</bold>), and Kir6.2 (<bold>C</bold>) protein levels. Data are expressed as fold change ratio on sham control and normalized to the β-actin protein levels. Bars represent the mean ± SEM obtained in 3 independent experiments, <italic>n</italic> = 7 for each group, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01.</p>
</caption>
<graphic xlink:href="biomedicines-08-00058-g004"></graphic>
</fig>
<table-wrap id="biomedicines-08-00058-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">biomedicines-08-00058-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>List of primers for RT–PCR.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Genes</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Forward Primer (5′–3′)</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reverse Primer (5′–3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Kcnj2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">GCAAACTCTGCTTGATGTGG</td>
<td align="center" colspan="1" rowspan="1" valign="middle">TCATACAAAGGGCTGTCTTCG</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>Kcnj3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CTGACCGCTTCACATAGC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CTCCAGACTGGGATAGAC</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>Kcnj11</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CCTACACCAGGTGGACATCC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CAGGCTGCGGTCCTCATCAA</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>